PMID: 8972111Dec 1, 1996Paper

Determination of leukemogenic benzene exposure concentrations: refined analyses of the Pliofilm cohort

Risk Analysis : an Official Publication of the Society for Risk Analysis
A R SchnatterM G Bird

Abstract

Biologic data on benzene metabolite doses, cytotoxicity, and genotoxicity often show that these effects do not vary directly with cumulative benzene exposure (i.e., concentration times time, or c x t). To examine the effect of an alternate exposure metric, we analyzed cell-type specific leukemia mortality in Pliofilm workers. The work history of each Pliofilm worker was used to define each worker's maximally exposed job/department combination over time and the associated long-term average concentration associated with the maximally exposed job (LTA-MEJ). Using this measure, in conjunction with four job exposure estimates, we calculated SMRs for groups of workers with increasing LTA-MEJs. The analyses suggest that a critical concentration of benzene exposure must be reached in order for the risk of leukemia or, more specifically, AMML to be expressed. The minimum concentration is between 20 and 60 ppm depending on the exposure estimate and endpoint (all leukemias or AMMLs only). We believe these analyses are a useful adjunct to previous analyses of the Pliofilm data. They suggests that (a) AMML risk is shown only above a critical concentration of benzene exposure, measured as a long-term average and experienced for years, (b) th...Continue Reading

References

Jul 9, 1977·Lancet·P F InfanteR J Young
Sep 11, 1992·Risk Analysis : an Official Publication of the Society for Risk Analysis·L A Cox, P F Ricci
Apr 1, 1992·Regulatory Toxicology and Pharmacology : RTP·F Y Bois, D G Paxman
Jul 1, 1992·Journal of Toxicology and Environmental Health·D J PaustenbachH D Peterson
Mar 1, 1990·Toxicology and Applied Pharmacology·C C TravisA D Arms
Jul 1, 1989·Environmental Health Perspectives·S M BrettV M Chinchilli
Mar 1, 1988·American Journal of Epidemiology·H AustinP Cole
Apr 23, 1987·The New England Journal of Medicine·R A RinskyP J Landrigan
Jan 1, 1987·Journal of Chronic Diseases·K S CrumpP W Crockett
Jan 1, 1981·American Journal of Industrial Medicine·R A RinskyA B Smith
May 1, 1995·American Journal of Industrial Medicine·D F Utterback, R A Rinsky
Jun 1, 1995·Occupational and Environmental Medicine·O Wong
Jan 1, 1994·Critical Reviews in Toxicology·R Snyder, G F Kalf
Apr 1, 1994·Risk Analysis : an Official Publication of the Society for Risk Analysis·M B PaxtonJ V Rodricks
Jun 1, 1994·Occupational and Environmental Medicine·K H WatanabeR C Spear
May 1, 1993·Stem Cells·R D Irons, W S Stillman
Jan 1, 1993·International Journal of Health Services : Planning, Administration, Evaluation·R Sass
Jan 1, 1996·International Archives of Occupational and Environmental Health·E DavoliR Fanelli
Dec 1, 1996·Environmental Health Perspectives·R D Irons, W S Stillman
Dec 1, 1996·Environmental Health Perspectives·R D Irons, W S Stillman
Oct 22, 1964·The New England Journal of Medicine·E C VIGLIANI, G SAITA

❮ Previous
Next ❯

Citations

May 15, 2003·Journal of Toxicology and Environmental Health. Part a·Pamela R D Williams, Dennis J Paustenbach
Jul 16, 2005·Journal of Occupational and Environmental Hygiene·Pamela R D Williams, Dennis J Paustenbach
Feb 27, 2004·Occupational and Environmental Medicine·L J BloemenG Marsh
Dec 19, 2000·Occupational and Environmental Medicine·R Duarte-DavidsonL Levy
Aug 26, 2003·Occupational and Environmental Medicine·J J CollinsD Shepperly
Oct 14, 2010·Critical Reviews in Toxicology·David GalbraithDennis Paustenbach
Jun 7, 2005·Chemico-biological Interactions·D C GlassM R Sim
May 17, 2006·Regulatory Toxicology and Pharmacology : RTP·Tung-Sheng ShihSaou-Hsing Liou
Nov 7, 2007·Human & Experimental Toxicology·Haseeb Ahmad Khan
Jun 27, 2017·Journal of Occupational and Environmental Hygiene·D C GlassL Rushton
Nov 22, 2008·Toxicology and Industrial Health·S WilburO Faroon
Sep 23, 2003·Epidemiology·Deborah C GlassRichard Manuell
Feb 6, 2010·Journal of Occupational and Environmental Medicine·Dominik D Alexander, Meghan E Wagner
Feb 5, 2008·Journal of Environmental Monitoring : JEM·Ijaz S Jamall, Calvin C Willhite
Dec 16, 2017·Critical Reviews in Toxicology·Sherilyn A Gross, Dennis J Paustenbach
May 11, 2018·Critical Reviews in Toxicology·Wenchao Li, A Robert Schnatter
Jan 12, 2021·Toxicology Letters·Colin M NorthStephen D Williams
Sep 18, 2020·Toxicology Letters·Colin M NorthStephen D Williams

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.